Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.63 |
| ▸ | CCR5 | P51681 | 3/20 | 0.63 |
| ▸ | CCR8 | P51685 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | METAP1 | P53582 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490247 | 0.85 | CCR1 (0.63) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL29545764 | 0.85 | CCR1 (0.63) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL604517 | 0.81 | CCR1 (0.59) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL25004067 | 0.80 | CCR1 (0.58) | CCR1CCR5CCR8KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL28907429 | 0.79 | CCR1 (0.79) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL517337 | 0.78 | CCR1 (1.00) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL23079802 | 0.77 | CCR1 (0.62) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL1442585 | 0.76 | TDP1 (0.68) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL24075503 | 0.76 | CCR1 (0.57) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL1536559 | 0.76 | KDM4E (0.61) | CCR1CCR5CCR8KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
| US-6372751-B1 | DRUGS WITH BENZENE AND PYRIMIDINE RINGS | BERLEX LABORATORIES, INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1135131-A4 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LAB (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135131-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6127376-A | A BLOOD FACTOR XA ENZYME INHIBITOR TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000033844-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LATORATORIES, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | CCR1 4122/4885CCR5 4253/4885CCR8 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.